malignant lung, cervical, ovarian, and mammary tissues,7 8 whereas Nagao like P1-ALP has been detected in non-malignant testicular as well as cervical tissues.7-1 This latter P1-ALP has also been termed placental like alkaline phosphatase.7
There has been recent interest in the evaluation of P1-ALP as a tumour marker using monoclonal antibodies specific for this isoenzyme. Circulating P1-ALP is found in low concentrations in some healthy individuals, however, especially cigarette smokers"' "; the most obvious origin would be from lung tissue, and the serum enzyme would thus be expected to be of the Regan the female smokers. In one male smoker and one female smoker the circulating P1-ALP activity was of an unusual type; it was unreactive with H317 (and hence not Regan type enzyme) and reactive with H17-E2 but L-leucine resistant (and hence clearly not Nagao type enzyme) (Figure) . This synplacental alkaline phosphatase was also found in the circulation of one of the male non-smokers, but none of the other healthy non-smokers had detectable concentrations (>0.1 U/i) of H17-E2 reactive P1-ALP. None of the non-smokers with chronic inflammatory lung disease had detectable amounts (>0-1 U/l) of circulating P1-ALP reactive with H317, but 4/11 (36%) did have trace amounts (mean + SD, 0-10 ± 0-08 U/I) of P1-ALP reactive with H17-E2 and sensitive to L-leucine inhibition (that is, Nagao type enzyme) (Figure) . with other tissue alkaline phosphatase isoenzymes. ' The enzyme immunoassay was performed as described previously. 12 Briefly, each monoclonal antibody was immobilised on to MicroElisa plate wells using rabbit antimouse immunoglobulin (Dakopatts A/S), and then test plasma samples were added at 1/3 dilution; any bound P1-ALP was subsequently detected by colour change in a phosphatase substrate. This assay has a lower limit of sensitivity of 0-1 U/I Pl-ALP.'2 All tests were performed in quadruplicate with alternate duplicates having 0-5 mM L-leucine included in the substrate solution so that parallel estimations of L-leucine sensitivity could be made.
Results
H317 reactive P1-ALP was not detected in the sera of any of the 16 healthy non-smokers or 12 healthy smokers using a lower limit in enzyme immunoassays of 0-1 U/l P1-ALP. In contrast, H17-E2 reactive Pl-ALP activity of >0-1 U/I was found in the sera of 5/7 (71 %) male smokers and 3/5 (60%) female smokers at concentrations of up to 1-7 U/I (Figure) . This activity (mean + SD, 0-39 + 0-49 U/l) was clearly inhibited by L-leucine (that is, Nagao type) in 4/5 (80%) of the male smokers and in 2/3 (67%) of Small amounts of circulating P1-ALP may be found in some non-pregnant individuals without malignancy,'°and this was clearly shown in 6/9 Pl-ALP positive cases to be of the carcinoplacental Nagao or closely related form of placental like alkaline phosphatase. This serum P1-ALP is characterised by being H317 unreactive, H17-E2 reactive, and sensitive to L-leucine inhibition, and is the form that is often found in raised concentrations in the sera of cigarette smokers. P1-ALP with such characteristics has previously been found only in malignant tissues and normal testicular and cervical tissue.5-7 9 Hence, the source of this normal circulating enzyme is unclear since tissue extracts from normal lung (of both smokers and non-smokers) (Williams and Johnson, unpublished observations) contain P1-ALP which is predominantly, if not all, of the Regan type.' Nevertheless, coexpression of both Nagao and Regan type enzyme has been reported in other tissue of both malignant and non-malignant origin, sometimes in widely differing proportions.7 8 '5 Thus, it is possible that small amounts of a Nagao type enzyme may be readily released from lung tissues. This is partly supported by the observation that occasional non-smoking patients with chronic inflammatory disease of either bronchial or parenchymal lung tissue had slightly raised serum P1-ALP concentrations, although the alternative explanation that cigarette smoking may promote release of a Nagao type (placental like) enzyme from another body organ remains a possibility. It will be of interest to determine, with sensitive enzyme immunoassays based on monoclonal antibodies, whether variations in serum P1-ALP reflect changes in any clinical disorders associated with cigarette smoking. 
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The trace amounts of serum P1-ALP found in three of the other healthy individuals may represent an unusual form related to the Nagao type enzyme. This was H317 unreactive and H17-E2 reactive, and hence antigenically resembled the Nagao (placental like) enzyme, but was not inhibited by L-leucine (unlike the Nagao type enzyme). This P1-ALP was heat stable at 65°C for 1 h. The only heat stable P1-ALP known to have this antigenic and biochemical profile is the homozygous 2-2 (FF) genetic phenotype of placenta derived P1-ALP.' This is found in about 9% of pregnancies.' Hence, it is possible that the similar P1-ALP found in trace amounts in occasional healthy non-pregnant sera may be a corresponding allotypic form of a Nagao like enzyme.
Cigarette smoking seems to have a pronounced effect on the production or cellular release, or both, of a carcinoplacental Nagao like P1-ALP. Indeed, the presence of this form of P1-ALP in the sera of healthy individuals restricts its use as a tumour marker.3 However, a sensitive assay able to identify accurately Regan type enzyme separately from Nagao type enzyme, such as that based on the H317 monoclonal antibody,7 2 may be a more specific carcinoplacental parameter.
